Clinical Trial Update: Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol evaluates binimetinib as a targeted treatment for cancers with NRAS alterations; results were posted in 2021 and the trial is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Malignant Neoplasm

Drugs mentioned

• Binimetinib (Mektovi) (binimetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-08-17